BirchBioMed Inc.
Teresa Brophy Bair currently serves as Chief Legal Officer at Kura Oncology, Inc. since October 2021, while also holding a board member position at BirchBioMed Inc. and serving on the Board of Advisors for Varia Ventures. Prior to these roles, Teresa was General Counsel and Senior Vice President at Athenex from June 2015 to October 2021, overseeing global legal matters and serving as Corporate Secretary. Teresa's extensive legal career includes a partnership at Harris Beach PLLC, where representation of Fortune 500 clients was accomplished, as well as prior positions at Roach, Brown, McCarthy & Gruber, P.C. and Zdarsky, Sawicki & Agostinelli. Educational background includes a Juris Doctor from the University at Buffalo School of Law and a Bachelor of Science in Business Administration from Bowling Green State University.
This person is not in any teams
This person is not in any offices
BirchBioMed Inc.
BirchBioMed Inc., a clinical-stage biomedical company focused on the clinical evaluation, development and commercialization of anti-scarring drugs, autoimmune therapeutics and novel strategies for transplantation. A University of British Columbia (“UBC”) spin-off, BirchBioMed holds the exclusive, worldwide pharmaceutical license from UBC for two medical therapeutic technologies that mark significant medical breakthroughs in the treatment of fibrosis and certain autoimmune diseases. Initially funded by key strategic donors and government bodies, including the Canadian Institute of Health Research and the Natural Sciences and Engineering Research Council of Canada (the Canadian counterpart of the U.S. National Institutes of Health), BirchBioMed's licensed technology has secured more than $6 million in government and association grants, coupled with additional university resources. It is also the first technology that UBC has advanced from discovery through Phase I clinical trials with support strictly from government/private donations.